SG11202111852TA - Therapeutic drug for dyskinesia - Google Patents
Therapeutic drug for dyskinesiaInfo
- Publication number
- SG11202111852TA SG11202111852TA SG11202111852TA SG11202111852TA SG11202111852TA SG 11202111852T A SG11202111852T A SG 11202111852TA SG 11202111852T A SG11202111852T A SG 11202111852TA SG 11202111852T A SG11202111852T A SG 11202111852TA SG 11202111852T A SG11202111852T A SG 11202111852TA
- Authority
- SG
- Singapore
- Prior art keywords
- dyskinesia
- therapeutic drug
- therapeutic
- drug
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/395,531 US10758535B1 (en) | 2019-04-26 | 2019-04-26 | Therapeutic drug for dyskinesia |
PCT/JP2020/017652 WO2020218487A1 (en) | 2019-04-26 | 2020-04-24 | Therapeutic drug for dyskinesia |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202111852TA true SG11202111852TA (en) | 2021-11-29 |
Family
ID=72241591
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202111852TA SG11202111852TA (en) | 2019-04-26 | 2020-04-24 | Therapeutic drug for dyskinesia |
Country Status (13)
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11559525B2 (en) | 2019-04-26 | 2023-01-24 | Sumitomo Pharma Co., Ltd. | Therapeutic drug for dyskinesia |
AU2021332775A1 (en) * | 2020-08-31 | 2023-04-27 | Sumitomo Pharma Co., Ltd. | Therapeutic agent for motor complications in parkinson's disease |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4507303A (en) | 1981-12-22 | 1985-03-26 | Sumitomo Chemical Company, Limited | Succinimide derivatives, compositions and method of use |
JPH11228414A (ja) | 1998-02-06 | 1999-08-24 | Sumitomo Pharmaceut Co Ltd | タンドスピロン経皮剤 |
CN101543497A (zh) * | 2002-01-28 | 2009-09-30 | 协和发酵工业株式会社 | 治疗运动疾病患者的方法 |
EP1743645A4 (en) * | 2004-06-01 | 2012-11-14 | Hisamitsu Pharmaceutical Co | ADHESIVE PATCH |
US7744918B2 (en) | 2004-11-22 | 2010-06-29 | Hisamitsu Pharmaceutical Co., Inc. | Drug-containing patch |
JP4873871B2 (ja) | 2005-02-28 | 2012-02-08 | 久光製薬株式会社 | 粘着剤及び貼付剤 |
JP5243254B2 (ja) | 2006-10-11 | 2013-07-24 | 久光製薬株式会社 | 結晶含有貼付剤 |
WO2013004249A1 (en) | 2011-07-05 | 2013-01-10 | Concit Pharma Aps | The use of serotonin receptor agonists for treatment of movement disorders |
MY169068A (en) * | 2012-04-18 | 2019-02-12 | Contera Pharma Aps | Orally available pharmaceutical formulation suitable for improved management of movement disorders |
CN113453683A (zh) * | 2018-12-20 | 2021-09-28 | 康特拉医药股份有限公司 | 运动障碍的治疗 |
-
2019
- 2019-04-26 US US16/395,531 patent/US10758535B1/en active Active
-
2020
- 2020-04-22 US US16/855,213 patent/US20210060015A1/en not_active Abandoned
- 2020-04-24 AU AU2020260895A patent/AU2020260895A1/en not_active Abandoned
- 2020-04-24 SG SG11202111852TA patent/SG11202111852TA/en unknown
- 2020-04-24 PH PH1/2021/552681A patent/PH12021552681A1/en unknown
- 2020-04-24 JP JP2021561833A patent/JP7695891B2/ja active Active
- 2020-04-24 KR KR1020217034115A patent/KR20220004640A/ko not_active Withdrawn
- 2020-04-24 CN CN202080029464.9A patent/CN113646045A/zh active Pending
- 2020-04-24 CA CA3137400A patent/CA3137400A1/en active Pending
- 2020-04-24 BR BR112021021184A patent/BR112021021184A8/pt not_active Application Discontinuation
- 2020-04-24 US US17/606,394 patent/US20220193075A1/en not_active Abandoned
- 2020-04-24 WO PCT/JP2020/017652 patent/WO2020218487A1/en unknown
- 2020-04-24 EA EA202192928A patent/EA202192928A1/ru unknown
- 2020-04-24 EP EP20794266.5A patent/EP3958972A4/en active Pending
- 2020-04-24 MX MX2021013070A patent/MX2021013070A/es unknown
-
2025
- 2025-02-04 JP JP2025017181A patent/JP2025072496A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US10758535B1 (en) | 2020-09-01 |
US20210060015A1 (en) | 2021-03-04 |
EP3958972A1 (en) | 2022-03-02 |
BR112021021184A2 (enrdf_load_stackoverflow) | 2021-12-14 |
JP2025072496A (ja) | 2025-05-09 |
MX2021013070A (es) | 2021-11-17 |
WO2020218487A1 (en) | 2020-10-29 |
US20220193075A1 (en) | 2022-06-23 |
PH12021552681A1 (en) | 2022-09-19 |
BR112021021184A8 (pt) | 2023-02-28 |
CA3137400A1 (en) | 2020-10-29 |
EP3958972A4 (en) | 2023-01-04 |
JP7695891B2 (ja) | 2025-06-19 |
CN113646045A (zh) | 2021-11-12 |
AU2020260895A1 (en) | 2021-12-23 |
JP2022529661A (ja) | 2022-06-23 |
KR20220004640A (ko) | 2022-01-11 |
EA202192928A1 (ru) | 2022-02-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB201911928D0 (en) | Pharmaceutical compounds | |
GB2572126B (en) | Pharmaceutical | |
GB2569961B (en) | Pharmaceutical | |
GB2572125B (en) | Pharmaceutical | |
GB201911944D0 (en) | Pharmaceutical compounds | |
SG11202103253YA (en) | Therapeutic compounds | |
GB201915273D0 (en) | Pharmaceutical compounds | |
PL4003293T3 (pl) | Rozwój farmaceutyczny | |
GB201915932D0 (en) | Pharmaceutical compounds | |
GB201914910D0 (en) | Pharmaceutical compounds | |
GB201807040D0 (en) | Drug delivery | |
GB201901989D0 (en) | Pharmaceutical combinations | |
GB201808150D0 (en) | Therapeutic compounds | |
SG11202111852TA (en) | Therapeutic drug for dyskinesia | |
GB201908885D0 (en) | Therapeutic compounds | |
IL291570A (en) | Pharmaceutical preparations | |
GB201909493D0 (en) | Therapeutic interactions | |
EP3655106A4 (en) | COMBINED INGREDIENTS THERAPY | |
IL283273A (en) | Pharmacy practices | |
HK40063860A (en) | Therapeutic drug for dyskinesia | |
ZA202105940B (en) | Drug delivery system | |
HK40112206A (en) | Therapeutic agents for neurodegenerative diseases | |
GB201911574D0 (en) | Therapeutic compounds | |
GB201911580D0 (en) | Therapeutic compounds | |
GB201914267D0 (en) | Pharmaceutical compounds |